UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 2, 2023
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [X] | Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] | No [X] |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 2 February 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Elisabeth Dahl Christensen |
2 | Reason for the notification | |
a) | Position/status | Member of the Board of Directors |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer | |
a) | Name | Novo Nordisk A/S |
b) | LEI | 549300DAQ1CVT6CXN342 |
4 | Details of the transaction(s) |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
1 |
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Liselotte Sofie Hyveled |
2 | Reason for the notification | |
a) | Position/status | Member of the Board of Directors |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer | |
a) | Name | Novo Nordisk A/S |
b) | LEI | 549300DAQ1CVT6CXN342 |
4 | Details of the transaction(s) | |
a) | Description of the financial instrument, type of instrument, | Shares |
Identification code | Novo Nordisk B DK0060534915 |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
2 |
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 1,345 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
1,345 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Liselotte Sofie Hyveled |
2 | Reason for the notification | |
a) | Position/status | Member of the Board of Directors |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer | |
a) | Name | Novo Nordisk A/S |
b) | LEI | 549300DAQ1CVT6CXN342 |
4 | Details of the transaction(s) | |
a) | Description of the financial instrument, type of instrument, | Shares |
Identification code | Novo Nordisk B DK0060534915 | |
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
3 |
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Mette Bøjer Jensen | |||
2 | Reason for the notification | ||||
a) | Position/status | Member of the Board of Directors | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
DKK 0.00 | 75 shares |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
4 |
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | ||
e) | Date of the transaction | 2023-02-01 | ||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Maha Kutay | |||
2 | Reason for the notification | ||||
a) | Position/status | Closely related to Kasim Kutay, member of the Board of Directors | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Purchase of shares | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 964.25 | 434 shares | ||||
d) | Aggregated information · Aggregated volume |
434 Shares |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
5 |
· Price | DKK 964.25 | |
e) | Date of the transaction | 2023-02-01 |
f) | Place of the transaction | NASDAQ COPENHAGEN A/S (XCSE) |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Thomas Rantzau | |||
2 | Reason for the notification | ||||
a) | Position/status | Member of the Board of Directors | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
6 |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
2 | Reason for the notification | ||||
a) | Position/status | President and CEO | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 86,083 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
86,083 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
7 |
a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
2 | Reason for the notification | ||||
a) | Position/status | President and CEO | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen |
2 | Reason for the notification |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
8 |
a) | Position/status | President and CEO | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Sale of shares | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 944.76 | 3,396 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
3,396 Shares DKK 944.76 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | AQUIS EXCHANGE EUROPE (AQEU) |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen |
2 | Reason for the notification | |
a) | Position/status | President and CEO |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer | |
a) | Name | Novo Nordisk A/S |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
9 |
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Sale of shares | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 942.91 | 13,847 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
13,847 Shares DKK 942.91 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | CBOE EUROPE (BEUP) |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen |
2 | Reason for the notification | |
a) | Position/status | President and CEO |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer | |
a) | Name | Novo Nordisk A/S |
b) | LEI | 549300DAQ1CVT6CXN342 |
4 | Details of the transaction(s) | |
a) | Description of the financial instrument, type of instrument, | Shares |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
10 |
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Sale of shares | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 939.70 | 77 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
77 Shares DKK 939.70 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | CBOE EUROPE - DXE DARK ORDER BOOK (NL) (CEUD) |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
2 | Reason for the notification | ||||
a) | Position/status | President and CEO | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Sale of shares | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
11 |
DKK 944.88 | 6,449 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
6,449 Shares DKK 944.88 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | CBOE EUROPE - DXE ORDER BOOKS (NL) (CEUX) |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
2 | Reason for the notification | ||||
a) | Position/status | President and CEO | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Sale of shares | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 944.03 | 3,503 shares | ||||
d) | Aggregated information |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
12 |
· Aggregated volume · Price | 3,503 Shares DKK 944.03 | |
e) | Date of the transaction | 2023-02-01 |
f) | Place of the transaction | SIGMA X EUROPE AUCTION BOOK (SGMV) |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
2 | Reason for the notification | ||||
a) | Position/status | President and CEO | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Sale of shares | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 942.74 | 38 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
38 Shares DKK 942.74 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | TURQUOISE EUROPE (TQEX) |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
13 |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
2 | Reason for the notification | ||||
a) | Position/status | President and CEO | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Sale of shares | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 943.23 | 22,690 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
22,690 Shares DKK 943.23 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | NASDAQ COPENHAGEN A/S (XCSE) |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Monique Carter |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
14 |
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 8,963 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
8,963 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Monique Carter |
2 | Reason for the notification | |
a) | Position/status | Executive Vice President |
b) | Initial notification/Amendment | Initial notification |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
15 |
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar |
2 | Reason for the notification | |
a) | Position/status | Executive Vice President |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer | |
a) | Name | Novo Nordisk A/S |
b) | LEI | 549300DAQ1CVT6CXN342 |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
16 |
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 26,984 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
26,984 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar |
2 | Reason for the notification | |
a) | Position/status | Executive Vice President |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer | |
a) | Name | Novo Nordisk A/S |
b) | LEI | 549300DAQ1CVT6CXN342 |
4 | Details of the transaction(s) | |
a) | Description of the financial instrument, type of instrument, | Shares |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
17 |
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar |
2 | Reason for the notification | |
a) | Position/status | Executive Vice President |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer | |
a) | Name | Novo Nordisk A/S |
b) | LEI | 549300DAQ1CVT6CXN342 |
4 | Details of the transaction(s) | |
a) | Description of the financial instrument, type of instrument, | Shares |
Identification code | Novo Nordisk B DK0060534915 | |
b) | Nature of the transaction | Sale of shares |
c) | Price(s) and volume(s) |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
18 |
Price(s) | Volume(s) | ||||
DKK 949.99 | 1,434 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
1,434 Shares DKK 949.99 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | OUTSIDE A TRADING VENUE |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 24,286 shares | ||||
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
19 |
d) | Aggregated information · Aggregated volume · Price |
24,286 Shares DKK 0.00 |
e) | Date of the transaction | 2023-02-01 |
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume |
75 Shares |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
20 |
· Price | DKK 0.00 | |
e) | Date of the transaction | 2023-02-01 |
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Sale of shares | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 949.99 | 6,929 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
6,929 Shares DKK 949.99 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | OUTSIDE A TRADING VENUE |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
21 |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 24,286 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
24,286 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
22 |
a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Douglas Langa |
2 | Reason for the notification |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
23 |
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 26,984 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
26,984 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Douglas Langa |
2 | Reason for the notification | |
a) | Position/status | Executive Vice President |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
24 |
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Douglas Langa |
2 | Reason for the notification | |
a) | Position/status | Executive Vice President |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer | |
a) | Name | Novo Nordisk A/S |
b) | LEI | 549300DAQ1CVT6CXN342 |
4 | Details of the transaction(s) |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
25 |
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Sale of shares | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 949.99 | 13,914 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
13,914 Shares DKK 949.99 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | OUTSIDE A TRADING VENUE |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange |
2 | Reason for the notification | |
a) | Position/status | Executive Vice President |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer | |
a) | Name | Novo Nordisk A/S |
b) | LEI | 549300DAQ1CVT6CXN342 |
4 | Details of the transaction(s) | |
a) | Description of the financial instrument, type of instrument, | Shares |
Identification code | Novo Nordisk B DK0060534915 | |
b) | Nature of the transaction | Other transaction (transfer of shares in |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
26 |
accordance with Long Term Incentive programme) | |||||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 10,978 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
10,978 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange |
2 | Reason for the notification | |
a) | Position/status | Executive Vice President |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer | |
a) | Name | Novo Nordisk A/S |
b) | LEI | 549300DAQ1CVT6CXN342 |
4 | Details of the transaction(s) | |
a) | Description of the financial instrument, type of instrument, | Shares |
Identification code | Novo Nordisk B DK0060534915 | |
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) |
c) | Price(s) and volume(s) |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
27 |
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Marcus Schindler | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 10,978 shares | ||||
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
28 |
d) | Aggregated information · Aggregated volume · Price |
10,978 Shares DKK 0.00 |
e) | Date of the transaction | 2023-02-01 |
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Marcus Schindler | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume |
75 Shares |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
29 |
· Price | DKK 0.00 | |
e) | Date of the transaction | 2023-02-01 |
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Marcus Schindler | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Sale of shares | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 944.96 | 5,000 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
5,000 Shares DKK 944.96 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | NASDAQ COPENHAGEN A/S (XCSE) |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
30 |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 24,286 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
24,286 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
31 |
a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Henrik Ehlers Wulff |
2 | Reason for the notification |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
32 |
a) | Position/status | Executive Vice President | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer | ||||
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 26,984 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
26,984 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name of the Board member/Executive/Associated Person | Henrik Ehlers Wulff |
2 | Reason for the notification | |
a) | Position/status | Executive Vice President |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
33 |
a) | Name | Novo Nordisk A/S | |||
b) | LEI | 549300DAQ1CVT6CXN342 | |||
4 | Details of the transaction(s) | ||||
a) | Description of the financial instrument, type of instrument, | Shares | |||
Identification code | Novo Nordisk B DK0060534915 | ||||
b) | Nature of the transaction | Other transaction (transfer of shares in accordance with restricted stock unit incentive programme) | |||
c) | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
DKK 0.00 | 75 shares | ||||
d) | Aggregated information · Aggregated volume · Price |
75 Shares DKK 0.00 | |||
e) | Date of the transaction | 2023-02-01 | |||
f) | Place of the transaction | Outside a trading venue |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
34 |
Contact for further information
Media: | |
Ambre Brown Morley +45 3079 9289 abmo@novonordisk.com | Natalia Salomao Abrahao (US) +1 848 304 1027 niaa@novonordisk.com |
Investors: | |
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
Company announcement No 6 / 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: February 2, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen Chief Executive Officer |